The main objective of the MITI2 project is to deliver an immunotherapy product ready to be used in a phase 1 clinical trial to treat IBD patients. The MITI2 project thus aims at provinding a preclinical package including :
- the proof of concept that a cellular immunotherapy using the identifies Treg subset represents a clinically suitable treatment for IBD patients
- an original gut-explant-based organoid preclinical model, which recapitulates ex vivo the complexity of intestinal physiology, but could also be used for other gut directed drug/cell therapy in the future.
This work has been funded by the European Union under the Horizon Europe Programme, as part of the project MITI² (Grant Agreement No. 101080445).
Company Details
- Founded
- -
- Address
- Nantes, Fr
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://miti2.eu
- Keywords
- Paris.
- HQ
- Nantes
Miti² Questions
Miti²'s website is http://miti2.eu
Miti²'s LinkedIn profile is https://fr.linkedin.com/company/miti2
Miti²'s industry is
Biotechnology Research
Miti²'s top competitors are
Leucocytop',
Scientex.eu,
Mathilde Fournière - Biotech Up,
Ami,
Incit (Immunologie Et Nouveaux Concepts En Immunothérapie),
Inserm,
Equipe 9 Child - Crci2na,
Eprobes,
Gate2tech,
Proact Eu-Response.
Miti²'s categories are Biotechnology Research
Miti²'s founding year is 2023
